Research Highlight |
Featured
-
-
-
Review Article |
Drug resistance in metastatic castration-resistant prostate cancer
This article reviews resistance to chemotherapy in metastatic castration-resistant prostate cancer (CRPC), which is a result of mechanisms of resistance specific to prostate cancer and to general mechanisms common to different cancer types. New therapies targeting these mechanisms are outlined and their potential impact in future and ongoing clinical trials is discussed. Knowledge of the mechanisms of drug resistance offers great hope for future effective therapy; however, drug resistance in metastatic CRPC is multifactorial and complex and the development of new medical therapies remains challenging.
- Bostjan Seruga
- , Alberto Ocana
- & Ian F. Tannock
-
Correspondence |
Lenalidomide for bortezomib-resistant multiple myeloma
- Chiara Briani
- , Tamara Berno
- & Renato Zambello
-
Correspondence |
Lenalidomide efficacy in bortezomib-resistant myeloma
- Alessandro Gozzetti
- , Rosaria Crupi
- & Monica Bocchia
-
-
Research Highlight |
Activated PI3K/AKT confers resistance to trastuzumab but not lapatinib
- Lisa Hutchinson
-
Review Article |
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
EGFR is one of the most studied targets in oncology, and several inhibitors have shown promising results in selected patient populations. However, intrinsic and acquired resistance to these targeted therapies is increasingly recognized. The authors of this Review describe the successful translation of EGFR inhibitors to the clinic, and highlight the mechanisms of resistance to these agents that limit their long-term efficacy. Understanding these processes will allow researchers to develop therapies that overcome resistance and ultimately lead to more successful outcomes.
- Deric L. Wheeler
- , Emily F. Dunn
- & Paul M. Harari
-
Case Study |
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma
This Case Study describes a patient with multiple myeloma and renal impairment who developed acute renal failure after three cycles of bortezomib-based primary therapy. Second-line lenalidomide and dexamethasone, with lenalidomide dose adjustment according to the patient's renal function, was well tolerated. This therapy elicited a rapid, durable partial tumor response and prompt improvement in the patient's kidney function.
- Heinz Ludwig
- & Niklas Zojer
-